The CONFIDENCE trial, a randomized controlled trial, demonstrated that the simultaneous initiation of finerenone and empagliflozin led to significantly greater reductions in the urinary albumin-to-creatinine ratio (UACR) compared with either therapy alone in patients with chronic kidney disease and type 2 diabetes. Combination therapy resulted in a substantial reduction in UACR and a greater achievement of clinically meaningful UACR reductions. The safety profile showed no unexpected signals, and researchers noted that the reduction in UACR occurred mostly within 4 weeks after therapy initiation, which is associated with a lower risk of adverse kidney outcomes.